Fawad Ali Shah | Neuropharmacology |

Posted on by Neuroscientists

Dr. Fawad Ali Shah | Neuropharmacology | Best Researcher Award

Dr. Fawad Ali Shah,  Prince Sattam bin Abdulaziz University, Saudi Arabia.

Dr. Fawad Ali Shah is an accomplished neuroscientist and pharmacologist whose academic journey began with a Pharm-D from the University of Malakand, Pakistan, and culminated in a Ph.D. in Neuroscience and Pharmacology from Gyeongsang National University, South Korea. With a strong foundation in neuroprotective pharmacology, his doctoral and postdoctoral research has focused on natural therapeutic agents for cerebral ischemia and brain injury. Professionally, he has held key academic roles in Pakistan, South Korea, Canada, and Saudi Arabia, currently serving as an Associate Professor at Prince Sattam Bin Abdulaziz University.

Profile

Scopus

🎓 Early Academic Pursuits

Dr. Fawad Ali Shah embarked on his academic journey with a profound interest in pharmaceutical sciences and neuroscience. He earned his Doctor of Pharmacy (Pharm-D) degree from the University of Malakand, Khyber Pakhtunkhwa, Pakistan, in 2010 with a First Division and a solid 70.88% score. His thesis, which explored ischemic and reperfusion injuries and their clinical implications, laid a strong foundation for his lifelong dedication to the neuropharmacological sciences. Driven by a deeper quest for knowledge, he pursued his Ph.D. at the esteemed Gyeongsang National University (GNU) in South Korea, where he specialized in neuroscience and pharmacology. Graduating with an A+ average in 2017, his doctoral research focused on investigating the neuroprotective effects of natural drug substances in models of cerebral ischemic injury. This blend of clinical insight and experimental pharmacology set the stage for his career in neuropharmacological research.

🧠 Professional Endeavors in Neuroscience

After earning his doctorate, Dr. Shah’s professional journey took a dynamic course across academia and clinical research institutions. He began as a Research Scholar and Lab Coordinator in the Neurobiology and Brain Histology Lab at GNU, deepening his technical expertise in neurohistology and preclinical pharmacology. Following this, he was appointed as Assistant Professor and then promoted to Associate Professor at Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad. His academic ascent continued with two prestigious postdoctoral positions: a lab-based postdoctoral fellowship at Robarts Research Institute, University of Western Ontario, Canada, and another at the University of Toronto. In 2022, he joined Prince Sattam Bin Abdulaziz University, Saudi Arabia, as an Associate Professor in the Department of Pharmacology and Toxicology. His teaching and mentorship roles have nurtured aspiring pharmacists and neuroscientists alike, while his hands-on work as a former Associate Pharmacist at GlaxoSmithKline (GSK) and Biogenics added vital industry experience to his academic pursuits.

🔬 Research Focus and Scientific Contributions

Dr. Shah’s research is anchored in the exploration of neuroprotective strategies, particularly involving natural drug substances in mitigating cerebral ischemia and related neuronal injuries. His scientific endeavors are characterized by a translational approach—bridging preclinical findings with potential therapeutic implications. Through a series of methodical investigations during his Ph.D. and postdoctoral tenures, he contributed to the understanding of ischemic brain injury mechanisms, drug-induced neuroprotection, and histopathological changes associated with brain trauma. He has significantly advanced the neuropharmacology discipline by contributing original research that addresses real-world health challenges, such as stroke and neurodegenerative conditions. His collaborations in Canadian research institutions have further enriched his methodological expertise and international research exposure.

📚 Teaching Excellence and Academic Impact

As a seasoned academic, Dr. Shah has been instrumental in delivering rigorous pharmacology and toxicology curricula to undergraduate and graduate pharmacy students. His dual role as a researcher and educator has empowered students with both theoretical understanding and laboratory proficiency. His mentorship extends beyond the classroom, guiding research projects and helping students build critical thinking in experimental neuroscience. His affiliation with academic institutions in Pakistan, South Korea, and Saudi Arabia demonstrates his global academic influence and his ability to adapt to diverse educational environments. His role in curriculum development and departmental leadership has contributed to the overall elevation of academic standards wherever he has served.

🏅 Recognition and Accolades

Dr. Fawad Ali Shah is an HEC (Higher Education Commission) Approved Supervisor, a recognition that attests to his academic merit and capability to guide M.Phil. and Ph.D. research. His scholarly distinction, demonstrated by first-class academic performance and international postdoctoral achievements, has earned him esteem in both academic and research circles. His involvement with reputed institutions like the University of Toronto and Robarts Research Institute has positioned him among globally recognized neuroscientists contributing to pharmacological innovation and brain research.

🌍 Global Reach and Influence

Dr. Shah’s academic and research footprints span several continents, including Asia, North America, and the Middle East. His international collaborations and transdisciplinary research have helped forge global scientific alliances. Through participation in international conferences, seminars, and research initiatives, he has disseminated key findings in neuropharmacology and inspired academic exchanges. His commitment to ethical and impactful research, along with his cross-border academic contributions, highlights his role as a globally engaged scholar advancing neuroscience for public health benefits.

🔮 Vision, Legacy, and Future Contributions

Looking ahead, Dr. Shah envisions expanding the therapeutic potential of natural compounds in managing neurodegenerative and cerebrovascular diseases. He aspires to establish advanced neuropharmacology labs in collaboration with global research centers to facilitate translational research and innovative drug discovery. His legacy lies in nurturing a new generation of neuroscientists, fostering research with clinical relevance, and strengthening the bridge between pharmaceutical education and neurological care. With a growing portfolio of impactful publications and international engagements, Dr. Shah is poised to remain a leading voice in neurotherapeutics and pharmacological innovation.

Publication

  1. Title: Carvacrol attenuated haloperidol-induced Parkinson’s disease via TNF/NFκβ-NLRP3-mediated pyroptosis
    Author(s): Not listed
    Year: 2025
    Journal: Laboratory Animal Research

 

  1. Title: In Silico molecular docking and molecular dynamic simulation of transferrin coated Phenytoin loaded SLNs with molecular targets of epilepsy
    Author(s): Not listed
    Year: 2025
    Journal: PLOS ONE

 

  1. Title: Carvacrol attenuated myocardial infarction through NLRP3-mediated pyroptosis and mTOR/Nrf2/PPARγ-dependent autophagic signaling
    Author(s): Not listed
    Year: 2025
    Journal: Toxicology and Applied Pharmacology

 

  1. Title: Retraction notice to “Quercetin attenuated ischemic stroke induced neurodegeneration by modulating glutamatergic and synaptic signaling pathways”
    Author(s): Not listed
    Year: 2024
    Journal: Heliyon

 

  1. Title: Ghrelin’s modulation of growth hormone secretagogue receptors in primary glioblastoma and meningioma: A comprehensive in-vitro study
    Author(s): Not listed
    Year: 2025
    Journal: Biochemical and Biophysical Research Communications

 

  1. Title: Corrigendum to “pH-Sensitive Tacrolimus loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease”
    Author(s): Not listed
    Year: 2024
    Journal: European Journal of Pharmaceutics and Biopharmaceutics

 

  1. Title: Punicalagin improves inflammation and oxidative stress in rat model of pelvic inflammatory disease
    Author(s): Not listed
    Year: 2025
    Journal: Natural Product Research

 

  1. Title: Core-shell tablets designed for modified and sequential release of ibuprofen and rabeprazole
    Author(s): Not listed
    Year: 2024
    Journal: International Journal of Pharmaceutics

 

  1. Title: Effect of Bacillus clausii in attenuating symptoms of DSS-induced ulcerative colitis by modulating NFkB pathway and oxidative stress in mice
    Author(s): Not listed
    Year: 2024
    Journal: Clinical and Experimental Pharmacology and Physiology

 

  1. Title: Paroxetine Loaded Nanostructured Lipid Carriers Based In-situ Gel for Brain Delivery via Nasal Route for Enhanced Anti-Depressant Effect: In Vitro Prospect and In Vivo Efficacy
    Author(s): Not listed
    Year: 2024
    Journal: AAPS PharmSciTech

 

🧾 Conclusion

Dr. Fawad Ali Shah stands out as a dedicated researcher, educator, and global academic contributor in the fields of neuroscience and pharmacology. His blend of international experience, pioneering research on natural neuroprotective agents, and commitment to academic excellence underscores his significant role in the advancement of neurotherapeutics. As he continues to inspire future scientists and lead innovative research, his impact will resonate across both the scientific and clinical communities, shaping the future of neurological health and pharmaceutical sciences.

Yanjie Wang | Neuropharmacology | Best Researcher Award

Posted on by Neuroscientists

Mr. Yanjie Wang | Neuropharmacology | Best Researcher Award

Mr. Yanjie Wang, Shanxi Medical University,  China.

Yanjie Wang is a dedicated Ph.D. candidate in Otorhinolaryngology at Shanxi Medical University, with a strong foundation in clinical medicine and academic research. After earning his M.S. in 2020, he served as a Lecturer and Physician at the Second Hospital of Shanxi Medical University. Since 2022, his doctoral work under Prof. Changqing Zhao has centered on the neuroimmune mechanisms of airway hyperresponsiveness, especially the TRPV1 pathway’s role in allergic rhinitis. With active involvement in multiple national and provincial research projects, over ten scientific publications, and conference presentations, Mr. Wang has made significant strides in linking basic science with clinical relevance. His research highlights the interplay between peripheral allergens and central neural pathways and suggests novel therapeutic avenues for allergic airway diseases.

Profile

Scopus

🎓 Early Academic Pursuits

Yanjie Wang embarked on his academic journey in medical science at Shanxi Medical University, where he demonstrated a strong commitment to otorhinolaryngological studies early on. He earned his Master of Science degree in 2020, laying a firm foundation in clinical and research methodologies. His academic curiosity and rigor soon led him to pursue a Ph.D. in Otorhinolaryngology under the mentorship of Professor Changqing Zhao, where he delved deeply into the intricacies of airway neuroimmune mechanisms. This academic progression marked the beginning of a promising research trajectory focusing on allergic airway disorders.

🩺 Professional Endeavors

Following his M.S. degree, Mr. Wang began his clinical career as a Lecturer and Physician at the Second Hospital of Shanxi Medical University. Balancing patient care with academic responsibilities, he gained valuable experience in both educational instruction and clinical practice. In 2022, he transitioned into full-time doctoral research, dedicating his efforts to understanding the interplay between peripheral inflammation and central nervous regulation in respiratory conditions. His dual background in clinical service and research gives him a unique perspective in translational medicine.

🔬 Contributions and Research Focus

Mr. Wang’s research centers on the neuroimmune interactions involved in airway hyperresponsiveness, particularly allergic rhinitis (AR). His investigations have highlighted the upregulation of TRPV1 channels in AR patients and their correlation with symptom severity, including sneezing and nasal itching. Furthermore, he elucidated the TRPV1-NF-κB pathway’s role in allergen-induced IL-33 secretion in human nasal epithelial cells (hNECs), identifying TRPV1 as a critical modulator of nasal immune responses. His findings further demonstrate that TRPV1 inhibition significantly reduces OVA-induced innate nasal epithelial activation, offering potential therapeutic implications.

🧪 Research Projects and Innovation

Through his active involvement in cutting-edge research, Mr. Wang has participated in three projects funded by the National Natural Science Foundation and led two significant provincial grants—namely the Basic Research Project of Shanxi Province (No. 202203021222390) and the Youth Project of the Second Hospital of Shanxi Medical University (No. 202302-9). These projects have advanced understanding of epithelial immune responses and neuroimmune regulation in allergic diseases. His ability to merge molecular biology, immunology, and clinical perspectives has positioned him as a rising voice in the field of upper airway disease research.

🏅 Accolades and Recognition

Yanjie Wang’s dedication to research and clinical advancement has resulted in more than ten peer-reviewed publications in SCI and other core journals. His work has not only been published but also presented at multiple national academic conferences, earning respect from peers and experts alike. His increasing citation index—marked by the notable 2025 publication on TRPV1 inhibition in nasal inflammation—reflects the relevance and growing impact of his work in both national and international scientific communities.

🌍 Impact and Influence

Mr. Wang’s studies contribute meaningfully to the understanding of allergic airway disease mechanisms, especially regarding epithelial-neural-immune crosstalk. His research outcomes have the potential to reshape therapeutic approaches for allergic rhinitis by targeting neuroimmune pathways rather than relying solely on antihistamines and corticosteroids. Through mentorship and interdisciplinary collaboration, he is fostering a network of emerging scholars and promoting evidence-based advancements in respiratory immunology.

🚀 Legacy and Future Contributions

Looking ahead, Yanjie Wang is poised to become a leading expert in airway neuroimmunology. His future ambitions include translating his basic research into clinical innovations that improve patient outcomes and developing novel therapeutic strategies targeting TRP channels in allergic diseases. His commitment to merging scientific exploration with clinical relevance ensures that his work will leave a lasting legacy in otorhinolaryngological research and patient care.

Publication

Title: Inhibition of TRPV1 attenuates innate nasal epithelial responses via NF-κB signaling pathway in allergic rhinitis
Authors: Wang, Yanjie; Qi, Xueping; Li, Hanxiong; Cheng, Fengli; Zhao, Changqing
Year: 2025

 

✅ Conclusion

Yanjie Wang stands out as a promising scholar whose work bridges clinical practice and experimental science. His research into TRPV1-mediated neuroimmune responses is not only timely but potentially transformative in treating allergic airway conditions. As he continues to deepen his investigations and expand his academic impact, his contributions are expected to drive innovation in the diagnosis, management, and therapy of upper airway disorders. His career trajectory signals a future leader in respiratory immunology and translational otorhinolaryngological research.